{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T09:28:28Z","timestamp":1790155708628,"version":"4.0.1"},"reference-count":108,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2017,3,15]],"date-time":"2017-03-15T00:00:00Z","timestamp":1489536000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0173358","type":"journal-article","created":{"date-parts":[[2017,3,15]],"date-time":"2017-03-15T18:18:59Z","timestamp":1489601939000},"page":"e0173358","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":84,"title":["Enzyme replacement therapy for Anderson-Fabry disease: A complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies"],"prefix":"10.1371","volume":"12","author":[{"given":"Regina","family":"El Dib","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huda","family":"Gomaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Politei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fellype","family":"Barreto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,3,15]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders","volume":"281","author":"PJ Meikle","year":"1999","journal-title":"JAMA"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset Fabry disease revealed by newborn screening","volume":"79","author":"M Spada","year":"2006","journal-title":"American Journal of Human Genetics"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"JM Aerts","year":"2008","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1093\/hmg\/ddv291","article-title":"Lyso-Gb3 activates Notch1 in human podocytes","volume":"24","author":"MD Sanchez-Ni\u00f1o","year":"2015","journal-title":"Hum Mol Genet"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A\u2014replacement therapy in Fabry\u2019s disease","volume":"345","author":"CM Eng","year":"2001","journal-title":"New England Journal of Medicine"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"R Schiffmann","year":"2001","journal-title":"JAMA"},{"issue":"Issue 7","key":"ref7","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006663.pub4","article-title":"Enzyme replacement therapy for Anderson-Fabry disease","author":"R El Dib","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"339","author":"D Moher","year":"2009","journal-title":"BMJ"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group","volume":"283","author":"DF Stroup","year":"2000","journal-title":"JAMA"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1590\/S0102-86502013001200010","article-title":"An alternative approach to deal with the absence of clinical trials: a proportional meta-analysis of case series studies","volume":"28","author":"R El Dib","year":"2013","journal-title":"Acta Cir Bras"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1464-410X.2011.10885.x","article-title":"Cryoablation versus Radiofrequency Ablation for the Treatment of Renal Cell Carcinoma: a meta-analysis of case series studies","volume":"110","author":"R El Dib","year":"2012","journal-title":"BJU Int"},{"key":"ref12","first-page":"7","article-title":"Effects of enzyme replacement therapy for cardiac-type Fabry patients with a Chinese hotspot late-onset Fabry mutation (IVS4+919G&gt;A)","volume":"3","author":"HY Lin","year":"2013","journal-title":"BMJ Open"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1445-5994.2008.01669.x","article-title":"Cardiovascular testing in Fabry disease: exercise capacity reduction, chronotropic incompetence and improved anaerobic threshold after enzyme replacement","volume":"38","author":"T Lobo","year":"2008","journal-title":"Intern Med J"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1093\/ndt\/gft452","article-title":"Long-term enzyme replacement therapy is associated with reduced proteinuria and preserved proximal tubular function in women with Fabry disease","volume":"29","author":"T Prabakaran","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1750-1172-8-47","article-title":"Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain","volume":"8","author":"SM Rombach","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ymgme.2014.01.014","article-title":"Outcomes of patients treated through the Canadian Fabry disease initiative","volume":"111","author":"SM Sirrs","year":"2014","journal-title":"Mol Genet Metab"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s10545-014-9717-4","article-title":"Long-term effectiveness of enzyme replacement therapy in Fabry disease: results from the NCS-LSD cohort study","volume":"37","author":"LJ Anderson","year":"2014","journal-title":"J Inherit Metab Dis"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Kantola I, Hietaharju A, Taurio J, Kananen K, Kantola T, Viikari J. Quality of life did not worsen for 7 years in enzyme-replacement therapy recipients with fabry disease. Clinical Therapeutics. Conference: 11th European Round Table on Fabry Disease Istanbul Turkey. Conference Start: 20101015 Conference End: 20101016. Conference Publication: (var.pagings). 34 (4 SUPPL. 1) (pp e21-e22), 2012.","DOI":"10.1016\/j.clinthera.2012.03.038"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1136\/heartjnl-2014-306278","article-title":"Cardiovascular outcomes in Fabry disease are linked to severity of chronic kidney disease","volume":"101","author":"AS Talbot","year":"2015","journal-title":"Heart"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s10545-014-9677-8","article-title":"Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta- analysis","volume":"37","author":"SM Rombach","year":"2014","journal-title":"Journal of Inherited Metabolic Disease"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"R DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"issue":"1","key":"ref22","doi-asserted-by":"crossref","first-page":"60","DOI":"10.2215\/CJN.03130411","article-title":"The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy","volume":"7","author":"S Feriozzi","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"ref23","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/gim.2013.53","article-title":"Analysis of left ventricular mass in untreated men and in men treated with agalsidase-beta: data from the Fabry Registry","volume":"15","author":"DP Germain","year":"2013","journal-title":"Genetics in medicine: official journal of the American College of Medical Genetics"},{"issue":"3","key":"ref24","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ymgme.2011.03.022","article-title":"Response of women with Fabry disease to enzyme replacement therapy: comparison with men, using data from FOS\u2014the Fabry Outcome Survey","volume":"103","author":"DA Hughes","year":"2011","journal-title":"Molecular genetics and metabolism"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13023-015-0338-2","article-title":"Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years&apos; treatment","volume":"10","author":"C Kampmann","year":"2015","journal-title":"Orphanet journal of rare diseases"},{"issue":"3","key":"ref26","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijcard.2008.03.007","article-title":"Onset and progression of the Anderson-Fabry disease related cardiomyopathy","volume":"130","author":"C Kampmann","year":"2008","journal-title":"International journal of cardiology"},{"issue":"4","key":"ref27","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","article-title":"Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta","volume":"66","author":"GE Linthorst","year":"2004","journal-title":"Kidney Int"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s13023-014-0169-6","article-title":"Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up study","volume":"9","author":"R Schiffmann","year":"2014","journal-title":"Orphanet J Rare Dis"},{"issue":"7","key":"ref29","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1093\/ndt\/gfp031","article-title":"Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy","volume":"24","author":"R Schiffmann","year":"2009","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"ref30","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1681\/ASN.2006111263","article-title":"Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing","volume":"18","author":"R Schiffmann","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"ref31","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ymgme.2014.01.014","article-title":"Outcomes of patients treated through the Canadian Fabry disease initiative","volume":"111","author":"SM Sirrs","year":"2014","journal-title":"Mol Genet Metab"},{"issue":"3","key":"ref32","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ymgme.2008.03.003","article-title":"Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3","volume":"94","author":"AC Vedder","year":"2008","journal-title":"Mol Genet Metab"},{"issue":"1","key":"ref33","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s10545-006-0484-8","article-title":"The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels","volume":"30","author":"AC Vedder","year":"2007","journal-title":"J Inherit Metab Dis"},{"key":"ref34","unstructured":"West M, Bichet D, Casey R, Clarke J, Sirrs S, LeMoine K. Benefit of enzyme replacement therapy in Fabry disease: Comparison of outcomes in the Canadian fabry disease initiative study.Molecular Genetics and Metabolism. Conference: 9th Annual Research Meeting of the Lysosomal Disease Network, WORLD Symposium, 2013 Orlando, FL United States. Conference Start: 20130212 Conference End: 20130215. Conference Publication: (var.pagings). 108 (2) (pp S97), 2013."},{"key":"ref35","unstructured":"Arash-Kaps L, Wachter M, Karabul N, Beck M, Kampmann C, Mengel E, et al. 10 years therapy with agalsidase A: Prevention of renal failure in male Fabry patients. Journal of Inherited Metabolic Disease. Conference: Annual Symposium of the Society for the Study of Inborn Errors of Metabolism, SSIEM 2014 Innsbruck Austria. Conference Start: 20140902 Conference End: 20140905. Conference Publication: (var.pagings). 37 (1 SUPPL. 1) (pp S145), 2014."},{"key":"ref36","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1023\/B:BOLI.0000005658.14563.77","article-title":"Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study","volume":"26","author":"F Baehner","year":"2003","journal-title":"J Inherit Metab Dis"},{"issue":"8","key":"ref37","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/j.1742-1241.2011.02695.x","article-title":"Fabry disease in Spain: description of Spanish patients and a comparison with other European countries using data from the Fabry Outcome Survey (FOS)","volume":"65","author":"M\u00c1 Barba-Romero","year":"2011","journal-title":"Int J Clin Pract"},{"issue":"10","key":"ref38","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.amjcard.2005.11.087","article-title":"Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry&apos;s cardiomyopathy","volume":"97","author":"M Beer","year":"2006","journal-title":"Am J Cardiol"},{"issue":"5","key":"ref39","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1399-0004.2012.01947.x","article-title":"Fabry disease in children: agalsidase-beta enzyme replacement therapy","volume":"83","author":"L Borgwardt","year":"2013","journal-title":"Clin Genet"},{"issue":"1","key":"ref40","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/1741826710391118","article-title":"Long-term changes in arterial structure and function and left ventricular geometry after enzyme replacement therapy in patients affected with Fabry disease","volume":"19","author":"C Collin","year":"2012","journal-title":"Eur J Prev Cardiol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1023\/B:BOLI.0000037342.59612.69","article-title":"Relief of gastrointestinal symptoms under enzyme replacement therapy in patients with Fabry disease","volume":"27","author":"FDR Dehout","year":"2004","journal-title":"Inherit Metab Dis"},{"issue":"4","key":"ref42","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1159\/000184389","article-title":"Natural history and treatment of uremia secondary to Fabry&apos;s disease: an European experience","volume":"46","author":"D Donati","year":"1987","journal-title":"Nephron"},{"key":"ref43","first-page":"S11","article-title":"Long term clinical outcomes in patients with Fabry disease receiving enzyme replacement therapy","volume":"114","author":"Douglas GJ McKechine","year":"2015","journal-title":"Molecular Genetics and Metabolism"},{"issue":"3","key":"ref44","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1136\/hrt.2004.054015","article-title":"Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A","volume":"92","author":"PM Elliott","year":"2006","journal-title":"Heart"},{"issue":"13","key":"ref45","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1157\/13093265","article-title":"Enfermedad de Fabry en Espa\u00f1a: primer an\u00e1lisis de la respuesta al tratamiento de sustituci\u00f3n enzim\u00e1tica","volume":"127","author":"RA Gallego","year":"2006","journal-title":"Medicina Cl\u00ednica"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1023\/B:BOLI.0000028726.11177.8b","article-title":"Clinical benefit in Fabry patients given enzyme replacement therapy\u2014A case series","volume":"27","author":"N Guffon","year":"2004","journal-title":"J Inherit MetabDis"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1136\/jmg.40.4.e38","article-title":"Clinical presentation in female patients with Fabry disease","volume":"40","author":"N Guffon","year":"2003","journal-title":"J Med Genet"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.cgh.2007.08.012","article-title":"Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy","volume":"5","author":"B Hoffmann","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Hopkin R, Mauer M, Lemay R, Strotmann J, Sims K. Fabry registry data indicate that early initiation of agalsidase beta treatment is associated with fewer clinical events. Molecular Genetics and Metabolism. Conference: 8th Annual Research Meeting of the Lysosomal Disease Network, WORLD Symposium 2012 San Diego, CA United States. Conference Start: 20120207 Conference End: 20120210. Conference Publication: (var.pagings). 105 (2) (pp S36), 2012.","DOI":"10.1016\/j.ymgme.2011.11.079"},{"issue":"2","key":"ref50","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.ymgme.2012.11.113","article-title":"Early initiation of agalsidase beta treatment is associated with fewer clinical events in women with Fabry disease: Data from the Fabry Registry","volume":"108","author":"R Hopkin","year":"2013","journal-title":"Molecular genetics and metabolism"},{"issue":"13","key":"ref51","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1136\/hrt.2008.162800","article-title":"Effects of enzyme-replacement therapy in patients with Anderson-Fabry disease: a prospective long-term cardiac magnetic resonance imaging study","volume":"95","author":"M Imbriaco","year":"2009","journal-title":"Heart"},{"issue":"1","key":"ref52","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s10545-006-0221-3","article-title":"The effect of 12-month enzyme replacement therapy on myocardial perfusion in patients with Fabry disease","volume":"29","author":"RJ Kalliokoski","year":"2006","journal-title":"J Inherit Metab Dis"},{"issue":"3","key":"ref53","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s10545-008-0848-3","article-title":"Twenty-four-month alpha-galactosidase A replacement therapy in Fabry disease has only minimal effects on symptoms and cardiovascular parameters","volume":"31","author":"JW Koskenvuo","year":"2008","journal-title":"J Inherit Metab Dis"},{"issue":"10","key":"ref54","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/eurheartj\/ehm153","article-title":"Cardiac manifestations of Anderson Fabry disease: results from the international Fabry outcome survey","volume":"28","author":"A Linhart","year":"2007","journal-title":"Eur Heart J"},{"issue":"4","key":"ref55","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/GIM.0b013e3181981d82","article-title":"Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease","volume":"11","author":"JC Lubanda","year":"2009","journal-title":"Genet Med"},{"issue":"11","key":"ref56","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females","volume":"38","author":"KD MacDermot","year":"2001","journal-title":"J Med Genet"},{"issue":"1\u20132","key":"ref57","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ymgme.2012.05.011","article-title":"Enzyme replacement therapy improves cardiac features and severity of Fabry disease","volume":"107","author":"M Motwani","year":"2012","journal-title":"Mol Genet Metab"},{"issue":"3","key":"ref58","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1399-0004.2008.01012.x","article-title":"Enzyme replacement therapy with agalsidase alfa in a cohort of Italian patients with Anderson-Fabry disease: testing the effects with the Mainz Severity Score Index","volume":"74","author":"R Parini","year":"2008","journal-title":"Clin Genet"},{"issue":"1","key":"ref59","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.ajkd.2005.03.016","article-title":"Enzyme replacement therapy in Fabry disease patients undergoing dialysis: effects on quality of life and organ involvement","volume":"46","author":"A Pisani","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1750-1172-8-47","article-title":"Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain","volume":"8","author":"SM Rombach","year":"2013","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"ref61","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1399-0004.2004.00284.x","article-title":"Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry&apos;s disease","volume":"66","author":"L Spinelli","year":"2004","journal-title":"Clin Genet"},{"issue":"4","key":"ref62","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/joim.12077","article-title":"Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications","volume":"274","author":"F Weidemann","year":"2013","journal-title":"J Intern Med"},{"issue":"6","key":"ref63","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/GIM.0b013e3181a23bec","article-title":"A 4-year study of the efficacy and tolerability of enzyme replacement therapy with agalsidase alfa in 36 women with Fabry disease","volume":"11","author":"C Whybra","year":"2009","journal-title":"Genet Med"},{"key":"ref64","unstructured":"Cybulla M, West M, Nicholls K, Torras J, Sunder-Plassmann G, Feriozzi S. Effectiveness and safety of enzyme replacement therapy (ERT) in acohort of kidney transplant recipients with fabry disease. Nephrology Dialysis Transplantation. Conference: 50th ERA-EDTA Congress Istanbul Turkey. Conference Start: 20130518 Conference End: 20130521. Conference Publication: (var.pagings). 28 (pp i287), 2013."},{"issue":"2","key":"ref65","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s10545-007-0521-2","article-title":"Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry","volume":"30","author":"CM Eng","year":"2007","journal-title":"J Inherit Metab Dis"},{"issue":"7","key":"ref66","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1097\/HJH.0b013e328336a077","article-title":"Enzyme replacement therapy improves cardiovascular responses to orthostatic challenge in Fabry patients","volume":"28","author":"MJ Hilz","year":"2010","journal-title":"J Hypertens"},{"issue":"9706","key":"ref67","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/S0140-6736(09)61493-8","article-title":"Enzyme replacement therapy with agalsidase alfa in patients with Fabry&apos;s disease: an analysis of registry data","volume":"374","author":"A Mehta","year":"2009","journal-title":"Lancet"},{"issue":"9","key":"ref68","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jacc.2010.11.018","article-title":"Cardiovascular events in patients with fabry disease natural history data from the fabry registry","volume":"57","author":"MR Patel","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"ref69","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1399-0004.2011.01671.x","article-title":"Fabry disease in children and response to enzyme replacement therapy: results from the Fabry Outcome Survey","volume":"81","author":"U Ramaswami","year":"2012","journal-title":"Clin Genet"},{"issue":"3","key":"ref70","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1542\/peds.2005-2895","article-title":"Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease","volume":"118","author":"M Ries","year":"2006","journal-title":"Pediatrics"},{"issue":"2","key":"ref71","first-page":"77","article-title":"Enzyme replacement therapy and renal function in 201 patients with Fabry disease","volume":"66","author":"A Schwarting","year":"2006","journal-title":"Clin Nephrol"},{"issue":"3","key":"ref72","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1161\/STROKEAHA.108.526293","article-title":"Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry","volume":"40","author":"K Sims","year":"2009","journal-title":"Stroke"},{"issue":"3","key":"ref73","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/ndt\/gfr420","article-title":"Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation","volume":"27","author":"DG Warnock","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"ref74","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/GIM.0b013e3181f13a4a","article-title":"Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: findings from the Fabry Registry","volume":"12","author":"T Watt","year":"2010","journal-title":"Genet Med"},{"issue":"4","key":"ref75","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jpeds.2007.09.007","article-title":"Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease","volume":"152","author":"JE Wraith","year":"2008","journal-title":"J Pediatr"},{"issue":"9","key":"ref76","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1093\/eurheartj\/ehp588","article-title":"Cardiovascular manifestations of Fabry disease: relationships between left ventricular hypertrophy, disease severity, and alpha-galactosidase A activity","volume":"31","author":"JC Wu","year":"2010","journal-title":"Eur Heart J"},{"issue":"2","key":"ref77","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00005792-200203000-00003","article-title":"Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course","volume":"81","author":"MH Branton","year":"2002","journal-title":"Medicine"},{"issue":"6","key":"ref78","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1212\/WNL.50.6.1746","article-title":"Quantitative analysis of cerebral vasculopathy in patients with Fabry disease","volume":"50","author":"KE Crutchfield","year":"1998","journal-title":"Neurology"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"Hebert A, Lacbawan L, Taber T, Goker-Alpan O. Evaluation of long-term enzyme replacement therapy for children with Fabry disease. Molecular Genetics and Metabolism. Conference: 9th Annual Research Meeting of the Lysosomal Disease Network, WORLD Symposium, 2013 Orlando, FL United States. Conference Start: 20130212 Conference End: 20130215. Conference Publication: (var.pagings). 108 (2) (pp S47), 2013.","DOI":"10.1016\/j.ymgme.2012.11.109"},{"key":"ref80","article-title":"Time to treatment benefit for adult patients with Fabry disease receiving agalsidase \u03b2: data from the Fabry Registry","author":"A Ortiz","year":"2016","journal-title":"J Med Genet"},{"issue":"3","key":"ref81","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/ndt\/gfp554","article-title":"End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry","volume":"25","author":"A Ortiz","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"ref82","doi-asserted-by":"crossref","unstructured":"Pano A, Goker-Alpan O, Longo N, McDonald M, Shankar S, Shen Y, Chang P, Schiffmann R. Safety and effect of open-label agalsidase alfa in treatment-naive children with Fabry disease. Molecular Genetics and Metabolism. Conference: 10th Annual Research Meeting of the Lysosomal Disease Network, WORLD Symposium, 2014 San Diego, CA United States. Conference Start: 20140210 Conference End: 20140213. Conference Publication: (var.pagings). 111 (2) (pp S84), 2014.","DOI":"10.1016\/j.ymgme.2013.12.201"},{"issue":"7","key":"ref83","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/ndt\/gfm096","article-title":"Safety and pharmacokinetics of agalsidase alfa in patients with Fabry disease and end-stage renal disease","volume":"22","author":"GM Pastores","year":"2007","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"ref84","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3346\/jkms.2008.23.2.243","article-title":"Short-term efficacy of enzyme replacement therapy in Korean patients with Fabry disease","volume":"23","author":"JH Choi","year":"2008","journal-title":"J Korean Med Sci"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10545-005-0575-y","article-title":"Enzyme replacement therapy in Japanese Fabry disease patients: the results of a phase 2 bridging study","volume":"28","author":"Y Eto","year":"2005","journal-title":"J Inherit Metab Dis"},{"issue":"6","key":"ref86","first-page":"295","article-title":"The cardiac effects of enzyme replacement therapy for fabry disease: Comparison of clinical course between female and male patients","volume":"122","author":"M Fujiwara","year":"2007","journal-title":"Tokyo Jikeikai Medical Journal"},{"key":"ref87","unstructured":"Goto H, Tsuboi K, Yamamoto H. Cardiac manifestations and enzyme replacement therapy of Fabry disease. Journal of Inherited Metabolic Disease. Conference: 12th International Congress of Inborn Errors of Metabolism, ICIEM 2013 Barcelona Spain. Conference Start: 20130903 Conference End: 20130906. Conference Publication: (var.pagings). 36 (2 SUPPL. 1) (pp S261), 2013."},{"key":"ref88","unstructured":"Kim JH, Cho JH, Lee BH, Choi JH, Yoo HW. Long-term efficacy of enzyme replacement therapy (ERT) for Fabry disease: Experience of single institution. Journal of Inherited Metabolic Disease. Conference: Annual Symposium of the Society for the Study of Inborn Errors of Metabolism, SSIEM 2015 Lyon France. Conference Start: 20150901 Conference End: 20150904. Conference Publication: (var.pagings). 38 (1 SUPPL. 1) (pp S265-S266), 2015."},{"issue":"Suppl 3","key":"ref89","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s10545-007-0740-6","article-title":"Clinical manifestations and natural history of Japanese heterozygous females with Fabry disease","volume":"31","author":"M Kobayashi","year":"2008","journal-title":"J Inherit Metab Dis"},{"issue":"suppl 1","key":"ref90","article-title":"Safety of enzyme replacement therapy among 20 japanese patients with classical type of fabry disease","volume":"28","author":"M Kobayashi","year":"2005","journal-title":"J Inherit Metab Dis"},{"key":"ref91","unstructured":"Tsuboi K, Yamamoto H, Goto H. Efficacy of enzyme replacement therapy with agalsidase alfa for 32 naive Fabry disease patients. Journal of Inherited Metabolic Disease. Conference: Annual Symposium of the Society for the Study of Inborn Errors of Metabolism, SSIEM 2015 Lyon France. Conference Start: 20150901 Conference End: 20150904. Conference Publication: (var.pagings). 38 (1 SUPPL. 1) (pp S291-S292), 2015a."},{"key":"ref92","unstructured":"Tsuboi K, Yamamoto H, Goto H, Ota A. Efficacy of enzyme replacement therapy with agalsidase beta for 17 naive Fabry disease patients. Journal of Inherited Metabolic Disease. Conference: Annual Symposium of the Society for the Study of Inborn Errors of Metabolism, SSIEM 2015 Lyon France. Conference Start: 20150901 Conference End: 20150904. Conference Publication: (var.pagings). 38 (1 SUPPL. 1) (pp S292), 2015b."},{"key":"ref93","doi-asserted-by":"crossref","first-page":"201","DOI":"10.33588\/rn.4304.2005610","article-title":"Dolor neurop\u00e1tico en la enfermedad de Fabry: remisi\u00f3n heterog\u00e9nea en tres a\u00f1os de tratamiento de reemplazo enzim\u00e1tico","volume":"43","author":"RO Dom\u00ednguez","year":"2006","journal-title":"Rev Neurol"},{"issue":"5","key":"ref94","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s10545-006-0339-3","article-title":"Improvement of sympathetic skin responses under enzyme replacement therapy in Fabry disease","volume":"29","author":"LB Jardim","year":"2006","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"ref95","first-page":"31","article-title":"Home infusion program for Fabry disease: experience with agalsidase alfa in Argentina","volume":"73","author":"I Kisinovsky","year":"2013","journal-title":"MEDICINA"},{"key":"ref96","first-page":"170","article-title":"Betagalsidase safety: Brazilian experience with patients under 16 years of age","volume":"12","author":"AM Martins","year":"2014","journal-title":"J.ymgme"},{"issue":"1","key":"ref97","doi-asserted-by":"crossref","first-page":"136","DOI":"10.4238\/2013.January.24.5","article-title":"Demographic characterization of Brazilian patients enrolled in the Fabry Registry","volume":"12","author":"AM Martins","year":"2013","journal-title":"Genet Mol Res"},{"issue":"9","key":"ref98","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3109\/08860220903150296","article-title":"Kidney Function and 24-Hour Proteinuria in Patients with Fabry Disease during 36 Months of Agalsidase Alfa Enzyme Replacement Therapy: A Brazilian Experience","volume":"31","author":"S Thofehrn","year":"2009","journal-title":"Ren Fail"},{"key":"ref99","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/j.ymgme.2015.12.307","article-title":"Comparison of integrated white blood cell alpha-galactosidase a activity exposure between every-other-day orally administered migalastat and biweekly infusions of agalsidase beta or agalsidase alfa","volume":"117","author":"FK Johnson","year":"2016","journal-title":"Mol Genet Metab"},{"key":"ref100","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1681\/ASN.2012030316","article-title":"Agalsidase benefits renal histology in young patients with Fabry disease","volume":"24","author":"C T\u00f8ndel","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"ref101","unstructured":"West M, Bichetb DG, Caseyc R, Clarked JTR, Iwanochkoe M, Khan A, et al. Canadian Fabry Disease Initiative Study (CFDI): 8 year outcomes of a randomized controlled trial of enzyme replacement therapy (ERT). <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/garrodsymposium.com\/garrod2016\/posters\/#p104\" xlink:type=\"simple\">http:\/\/garrodsymposium.com\/garrod2016\/posters\/#p104<\/ext-link>. Accessed on July 18, 2016."},{"key":"ref102","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.ajhg.2009.11.001","article-title":"Meta-analysis of genome-wide association studies with overlapping subjects","volume":"85","author":"DY Lin","year":"2009","journal-title":"Am J Hum Genet"},{"issue":"2","key":"ref103","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease: a randomized trial","volume":"146","author":"M Banikazemi","year":"2007","journal-title":"Ann Intern Med"},{"key":"ref104","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1365-2753.2007.00886.x","article-title":"Mapping the Cochrane evidence for decision making in health care","volume":"13","author":"RP El Dib","year":"2007","journal-title":"J Eval Clin Pract"},{"key":"ref105","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1365-2753.2012.01877.x","article-title":"Systematic reviews showed insufficient evidence for clinical practice in 2004: what about in 2011? The next appeal for the evidence-based medicine age","volume":"19","author":"PJ Villas Boas","year":"2013","journal-title":"J Eval Clin Pract"},{"key":"ref106","doi-asserted-by":"crossref","first-page":"376","DOI":"10.7326\/0003-4819-126-5-199703010-00006","article-title":"Systematic reviews: synthesis of best evidence for clinical decisions","volume":"126","author":"DJ Cook","year":"1997","journal-title":"Ann Intern Med"},{"key":"ref107","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1136\/bmj.326.7387.475","article-title":"Survey of claims of no effect in abstracts of Cochrane reviews","volume":"326","author":"P Alderson","year":"2003","journal-title":"BMJ"},{"issue":"Issue 3","key":"ref108","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD010324.pub2","article-title":"Enzyme replacement and substrate reduction therapy for Gaucher disease","author":"E Shemesh","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0173358","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T22:06:29Z","timestamp":1750111589000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0173358"}},"subtitle":[],"editor":[{"given":"Leighton R","family":"James","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,3,15]]},"references-count":108,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,3,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0173358","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,15]]}}}